

The Biology Behind

Hypoxia and Metastasis.

□□ *Commentary on Rofstad et al., p. 1971*

Naz Chaudary and Richard P. Hill1947

Molecular Pathways

Unraveling the Mechanisms of Endocrine Resistance in Breast Cancer: New Therapeutic Opportunities.

Suleiman Massarweh and Rachel Schiff1950

Targeting Checkpoint Kinase 1 in Cancer Therapeutics.

Archie N. Tse, Richard Carvajal, and Gary K. Schwartz1955

Review

The Potential of Antiangiogenic Therapy in Non-Small Cell Lung Cancer.

Giuseppe Giaccone1961

Human Cancer Biology

Fluctuating and Diffusion-Limited Hypoxia in Hypoxia-Induced Metastasis.

Einar K. Rofstad, Kanthi Galappathi, Berit Mathiesen, and Else-Beate M. Ruud1971

β -2-Microglobulin Is an Androgen-Regulated Secreted Protein Elevated in Serum of Patients with Advanced Prostate Cancer.

Mitchell Gross, Irina Top, Isett Laux, Jonathan Katz, John Curran, Charles Tindell, and David Agus1979

Estrogen Receptor β Expression Is Associated with Tamoxifen Response in ER α -Negative Breast Carcinoma.

Sofia K. Gruvberger-Saal, Pär-Ola Bendahl, Lao H. Saal, Mervi Laakso, Cecilia Hegardt, Patrik Edén, Carsten Peterson, Per Malmström, Jorma Isola, Åke Borg, and Märten Fernö1987

3q26 Amplification and Polysomy of Chromosome 3 in Squamous Cell Lesions of the Lung: A Fluorescence *In situ* Hybridization Study.

Giuseppe Pelosi, Barbara Del Curto, Maurizio Trubia, Andrew G. Nicholson, Michela Manzotti, Giulia Veronesi, Lorenzo Spaggiari, Patrick Maisonneuve, Felice Pasini, Alberto Terzi, Antonio Iannucci, and Giuseppe Viale1995

Molecular Characterization of Waldenstrom's Macroglobulinemia Reveals Frequent Occurrence of Two B-Cell Clones Having Distinct IgH VDJ Sequences.

Jitra Kriangkum, Brian J. Taylor, Steven P. Treon, Michael J. Mant, Tony Reiman, Andrew R. Belch, and Linda M. Pilarski2005

Imaging, Diagnosis, Prognosis

Population-Based Molecular Prognosis of Breast Cancer by Transcriptional Profiling.

Yan Ma, Yong Qian, Liang Wei, Jame Abraham, Xianglin Shi, Vincent Castranova, E. James Harner, Daniel C. Flynn, and Lan Guo2014

Circulating Tumor Cell Analysis in Patients with Progressive Castration-Resistant Prostate Cancer. David R. Shaffer, Margaret A. Leversha, Daniel C. Danila, Oscar Lin, Rita Gonzalez-Espinoza, Bin Gu, Aseem Anand, Katherine Smith, Peter Maslak, Gerald V. Doyle, Leon W.M.M. Terstappen, Hans Lilja, Glenn Heller, Martin Fleisher, and Howard I. Scher	2023
Adrenal Androgen Levels as Predictors of Outcome in Prostate Cancer Patients Treated with Ketoconazole Plus Antiandrogen Withdrawal: Results from a Cancer and Leukemia Group B Study. Charles J. Ryan, Susan Halabi, San-San Ou, Nicholas J. Vogelzang, Philip Kantoff, Eric J. Small, and for the Cancer and Leukemia Group B.....	2030
Loss of the Mismatch Repair Protein MSH6 in Human Glioblastomas Is Associated with Tumor Progression during Temozolomide Treatment. Daniel P. Cahill, Kymberly K. Levine, Rebecca A. Betensky, Patrick J. Codd, Candice A. Romany, Linsey B. Reavie, Tracy T. Batchelor, P. Andrew Futreal, Michael R. Stratton, William T. Curry, A. John Iafrate, and David N. Louis.....	2038
Promoter Hypermethylation Identifies Progression Risk in Bladder Cancer. David R. Yates, Ishtiaq Rehman, Maysam F. Abbod, Mark Meuth, Simon S. Cross, Derek A. Linkens, Freddie C. Hamdy, and James W.F. Catto.....	2046
Plasma Matrix Metalloproteinase-9 Level Is Better than Serum Matrix Metalloproteinase-9 Level to Predict Gastric Cancer Evolution. Chun-Ying Wu, Ming-Shiang Wu, En-Pei Chiang, Yi-Ju Chen, Chien-Jen Chen, Nai-Hui Chi, Ying-Ting Shih, Gran-Hum Chen, and Jaw-Town Lin.....	2054
Microtubule-Associated Protein-tau is a Bifunctional Predictor of Endocrine Sensitivity and Chemotherapy Resistance in Estrogen Receptor-Positive Breast Cancer. Fabrice Andre, Christos Hatzis, Keith Anderson, Christos Sotiriou, Chafika Mazouni, Jaime Mejia, Bailiang Wang, Gabriel N. Hortobagyi, W. Fraser Symmans, and Lajos Pusztai	2061
Utility of Circulating B-RAF DNA Mutation in Serum for Monitoring Melanoma Patients Receiving Biochemotherapy. Masaru Shinozaki, Steven J. O'Day, Minoru Kitago, Farin Amersi, Christine Kuo, Joseph Kim, He-Jing Wang, and Dave S.B. Hoon.....	2068
Tumor-Infiltrating Foxp3⁺CD4⁺CD25⁺ T Cells Predict Poor Survival in Renal Cell Carcinoma. Sameer A. Siddiqui, Xavier Frigola, Sandra Bonne-Annee, Maria Mercader, Susan M. Kuntz, Amy E. Krambeck, Shomik Sengupta, Haidong Dong, John C. Cheville, Christine M. Lohse, Christopher J. Krco, W. Scott Webster, Bradley C. Leibovich, Michael L. Blute, Keith L. Knutson, and Eugene D. Kwon	2075
Stromal Myofibroblasts Predict Disease Recurrence for Colorectal Cancer. Tadashi Tsujino, Iwao Seshimo, Hirofumi Yamamoto, Chew Yee Ngan, Koji Ezumi, Ichiro Takemasa, Masataka Ikeda, Mitsugu Sekimoto, Nariaki Matsuura, and Morito Monden	2082

Cancer Therapy: Clinical

A Phase I Pharmacokinetic and Pharmacodynamic Study of S-3304, a Novel Matrix Metalloproteinase Inhibitor, in Patients with Advanced and Refractory Solid Tumors. Alberto A. Chiappori, S. Gail Eckhardt, Ronald Bukowski, Daniel M. Sullivan, Minoru Ikeda, Yoshitaka Yano, Takuko Yamada-Sawada, Yoshikaze Kambayashi, Kazushige Tanaka, Milind M. Javle, Tarek Mekhail, Cindy L. O'Bryant, and Patrick J. Creaven	2091
Effects of the Administration of High-Dose Interleukin-2 on Immunoregulatory Cell Subsets in Patients with Advanced Melanoma and Renal Cell Cancer. Hans J.J. van derVliet, Henry B. Koon, Simon C. Yue, Burak Uzunparmak, Virginia Seery, Marc A. Gavin, Alexander Y. Rudensky, Michael B. Atkins, Steven P. Balk, and Mark A. Exley.....	2100

A Phase I Pharmacokinetic and Pharmacodynamic Study of PX-12, a Novel Inhibitor of Thioredoxin-1, in Patients with Advanced Solid Tumors. Ramesh K. Ramanathan, D. Lynn Kirkpatrick, Chandra P. Belani, David Friedland, Sylvan B. Green, H-H. Sherry Chow, Catherine A. Cordova, Steven P. Stratton, Elizabeth R. Sharlow, Amanda Baker, and Tomislav Dragovich.....	2109
Angiopoietin 2 Is a Potential Mediator of High-Dose Interleukin 2–Induced Vascular Leak. Diana C. Gallagher, Rupal S. Bhatt, Samir M. Parikh, Parin Patel, Virginia Seery, David F. McDermott, Michael B. Atkins, and Vikas P. Sukhatme	2115
Evaluation of Plasma Insulin-like Growth Factor Binding Protein 2 and Her-2 Extracellular Domain as Biomarkers for 17-Allylamino-17-Demethoxygeldanamycin Treatment of Adult Patients with Advanced Solid Tumors. Julie L. Eiseman, Jianxia Guo, Ramesh K. Ramanathan, Chandra P. Belani, David B. Solit, Howard I. Scher, S. Percy Ivy, Eleanor G. Zuhowski, and Merrill J. Egorin.....	2121
Phase I Evaluation of a Fully Human Anti-α_v Integrin Monoclonal Antibody (CNTO 95) in Patients with Advanced Solid Tumors. Saifee A. Mullamitha, Nhuan C. Ton, Geoff J.M. Parker, Alan Jackson, Peter J. Julyan, Caleb Roberts, Gio A. Buonaccorsi, Yvonne Watson, Karen Davies, Sue Cheung, Lynn Hope, Juan W. Valle, John A. Radford, Jeremy Lawrance, Mark P. Saunders, Mihaela C. Munteanu, Marian T. Nakada, Jeffrey A. Nemeth, Hugh M. Davis, Qun Jiao, Uma Prabhakar, Zhihui Lang, Robert E. Corringham, Robert A. Beckman, and Gordon C. Jayson in association with the Biotherapy Development Association	2128

Cancer Therapy: Preclinical

5-Aza-2'-Deoxycytidine Delays Androgen-Independent Disease and Improves Survival in the Transgenic Adenocarcinoma of the Mouse Prostate Mouse Model of Prostate Cancer. Christoph S. Zorn, Kirk J. Wojno, Michael T. McCabe, Rainer Kuefer, Juergen E. Gschwend, and Mark L. Day	2136
Mcl-1 Is a Relevant Therapeutic Target in Acute and Chronic Lymphoid Malignancies: Down-Regulation Enhances Rituximab-Mediated Apoptosis and Complement-Dependent Cytotoxicity. Syed-Rehan A. Hussain, Carolyn M. Cheney, Amy J. Johnson, Thomas S. Lin, Michael R. Grever, Michael A. Caligiuri, David M. Lucas, and John C. Byrd.....	2144
Clinical Significance and Therapeutic Potential of the Programmed Death-1 Ligand/Programmed Death-1 Pathway in Human Pancreatic Cancer. Takeo Nomi, Masayuki Sho, Takahiro Akahori, Kaoru Hamada, Atsushi Kubo, Hiromichi Kanehiro, Shinji Nakamura, Koji Enomoto, Hideo Yagita, Miyuki Azuma, and Yoshiyuki Nakajima	2151
Systemic CTLA-4 Blockade Ameliorates Glioma-Induced Changes to the CD4⁺ T Cell Compartment without Affecting Regulatory T-Cell Function. Peter E. Fecci, Hidenobu Ochiai, Duane A. Mitchell, Peter M. Grossi, Alison E. Sweeney, Gary E. Archer, Thomas Cummings, James P. Allison, Darell D. Bigner, and John H. Sampson.....	2158
Accelerated Preclinical Testing Using Transplanted Tumors from Genetically Engineered Mouse Breast Cancer Models. Lyuba Varticovski, Melinda G. Hollingshead, Ana I. Robles, Xiaolin Wu, James Cherry, David J. Munroe, Luanne Lukes, Miriam R. Anver, John P. Carter, Suzanne D. Borgel, Howard Stotler, Carrie A. Bonomi, Nomelí P. Nunez, Stephen D. Hursting, Wenhui Qiao, Chuxia X. Deng, Jeff E. Green, Kent W. Hunter, Glenn Merlino, Patricia S. Steeg, Lalage M. Wakefield, and J. Carl Barrett	2168

Transfection with Anti-p65 Intrabody Suppresses Invasion and Angiogenesis in Glioma Cells by Blocking Nuclear Factor-κB Transcriptional Activity. Liang Li, Christopher S. Gondi, Dzung H. Dinh, William C. Olivero, Meena Gujrati, and Jasti S. Rao.....	2178
The Therapeutic Potential of Hepatocyte Growth Factor to Sensitize Ovarian Cancer Cells to Cisplatin and Paclitaxel <i>In vivo</i>. Chiara Bardella, Daniela Dettori, Martina Olivero, Nadia Coltella, Massimiliano Mazzone, and Maria Flavia Di Renzo	2191
Chemosensitization of Cancer <i>In vitro</i> and <i>In vivo</i> by Nitric Oxide Signaling. Lisa J. Frederiksen, Richard Sullivan, Lori R. Maxwell, Shannyn K. Macdonald-Goodfellow, Michael A. Adams, Brian M. Bennett, D. Robert Siemens, and Charles H. Graham	2199
Potent siRNA Inhibitors of Ribonucleotide Reductase Subunit RRM2 Reduce Cell Proliferation <i>In vitro</i> and <i>In vivo</i>. Jeremy D. Heidel, Joanna Yi-Ching Liu, Yun Yen, Bingsen Zhou, Bret S.E. Heale, John J. Rossi, Derek W. Bartlett, and Mark E. Davis	2207
Selective Tumor Targeting by the Hypoxia-Activated Prodrug AQ4N Blocks Tumor Growth and Metastasis in Preclinical Models of Pancreatic Cancer. Alshad S. Lalani, Susan E. Alters, Alvin Wong, Mark R. Albertella, Jeffrey L. Cleland, and William David Henner.....	2216
Preclinical Studies of TW-37, a New Nonpeptidic Small-Molecule Inhibitor of Bcl-2, in Diffuse Large Cell Lymphoma Xenograft Model Reveal Drug Action on Both Bcl-2 and Mcl-1. Ramzi M. Mohammad, Anton Scott Goustin, Amro Aboukameel, Ben Chen, Sanjeev Banerjee, Guoping Wang, Zaneta Nikolovska-Coleska, Shaomeng Wang, and Ayad Al-Katib.....	2226
Menatetrenone, a Vitamin K2 Analogue, Inhibits Hepatocellular Carcinoma Cell Growth by Suppressing Cyclin D1 Expression through Inhibition of Nuclear Factor κB Activation. Iwata Ozaki, Hao Zhang, Toshihiko Mizuta, Yasushi Ide, Yuichiro Eguchi, Tsutomu Yasutake, Toshiyuki Sakamaki, Richard G. Pestell, and Kyosuke Yamamoto	2236
c-Met Is a Potentially New Therapeutic Target for Treatment of Human Melanoma. Neelu Puri, Salman Ahmed, Varalakshmi Janamanchi, Maria Tretiakova, Osvaldo Zumba, Thomas Krausz, Ramasamy Jagadeeswaran, and Ravi Salgia.....	2246
Identification of Molecular Predictors of Response in a Study of Tipifarnib Treatment in Relapsed and Refractory Acute Myelogenous Leukemia. Mitch Raponi, Jean-Luc Harousseau, Jeffrey E. Lancet, Bob Löwenberg, Richard Stone, Yi Zhang, Wayne Rackoff, Yixin Wang, and David Atkins	2254
Synergism between Arsenic Trioxide and Heat Shock Protein 90 Inhibitors on Signal Transducer and Activator of Transcription Protein 3 Activity—Pharmacodynamic Drug-Drug Interaction Modeling. Meir Wetzler, Justin C. Earp, Michael T. Brady, Michael K. Keng, and William J. Jusko	2261
The Therapeutic and Preventive Effect of RRR-α-Vitamin E Succinate on Prostate Cancer via Induction of Insulin-Like Growth Factor Binding Protein-3. Yi Yin, Jing Ni, Ming Chen, Matthew A. DiMaggio, Yinglu Guo, and Shuyuan Yeh	2271

Cancer Prevention


Identification of a Highly Effective Rapamycin Schedule that Markedly Reduces the Size, Multiplicity, and Phenotypic Progression of Tobacco Carcinogen-Induced Murine Lung Tumors. Courtney A. Granville, Noel Warfel, Junji Tsurutani, M. Christine Hollander, Matthew Robertson, Stephen D. Fox, Timothy D. Veenstra, Haleem J. Issaq, R. Ilona Linnoila, and Phillip A. Dennis	2281
--	------

Morin (3,5,7,2',4'-Pentahydroxyflavone) Abolishes Nuclear Factor- κ B Activation Induced by Various Carcinogens and Inflammatory Stimuli, Leading to Suppression of Nuclear Factor- κ B-Regulated Gene Expression and Up-regulation of Apoptosis. Sunil K. Manna, Rishi S. Aggarwal, Gautam Sethi, Bharat B. Aggarwal, and Govindarajan T. Ramesh.....2290

Selective Killing of Cancer Cells by Leaf Extract of Ashwagandha: Identification of a Tumor-Inhibitory Factor and the First Molecular Insights to Its Effect. Nashi Widodo, Kamaljit Kaur, Bhupal G. Shrestha, Yasuomi Takagi, Tetsuro Ishii, Renu Wadhwa, and Sunil C. Kaul.....2298

About the Cover

Immunohistochemistry of a glioblastoma tumor specimen with monoclonal antibodies specific for the mismatch repair protein MSH6. Loss of MSH6 is found in recurrent glioblastomas and is associated with the progressive growth of these tumors while they are under treatment with the alkylating chemotherapeutic agent temozolomide. Because mismatch repair deficiency is known to mediate alkylator drug resistance *in vitro*, and temozolomide is a component of the standard-of-care treatment for glioblastoma, the finding of MSH6 loss in glioblastoma recurrences links the well-established *in vitro* phenomenon to the most common clinical treatment scenario encountered in the care of neuro-oncology patients. For further details, please see Cahill *et al.* on page 2038 of this issue.



Clinical Cancer Research

13 (7)

Clin Cancer Res 2007;13:1947-2306.

Updated version Access the most recent version of this article at:
<http://clincancerres.aacrjournals.org/content/13/7>

E-mail alerts [Sign up to receive free email-alerts](#) related to this article or journal.

Reprints and Subscriptions To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions To request permission to re-use all or part of this article, use this link <http://clincancerres.aacrjournals.org/content/13/7>. Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.